Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Videos|January 31, 2022
Increased financial coverage for Rezum therapy reaps benefits for patients with BPH
Author(s)Urology Times staff
“I think now the government has realized…the work that’s involved in this procedure…[and] we’re now being reimbursed at an appropriate level,” says David M. Albala, MD.
Advertisement
In this video, David M. Albala, MD, discusses how the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy will open the doors for more patients to receive this minimally invasive treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Advertisement
Related to this article
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
3
Infertility care: Examining geographic gaps in access
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5